Drug news
Xience Prime/Xience V stents as alternative to CAGB in EXCEL trial
Abbott Vascular announces the enrollment of the first patients in the EXCEL study which will assess the safety and effectiveness of the Xience Prime/Xience V everolimus eluting coronary stent as an alterantie to coronary artery by pass grafting (CABG) in patients with Left Main Disease, a high risk sub set of Coronary Artery Disease.Joseph Sabik, M.D., chairman, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic and Greg W. Stone, M.D., professor of medicine at Columbia University Medical Center and NewYork-Presbyterian Hospital are investigators
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.